Clinical Trials in Willowbrook, Illinois
21 recruiting
Showing 1–20 of 21 trials
Recruiting
Phase 3
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Janssen Research & Development, LLC600 enrolled69 locationsNCT07438496
Recruiting
Phase 2
A Study of SPY072 in Rheumatic Disease
Rheumatoid ArthritisPsoriatic ArthritisRheumatic Diseases+5 more
Spyre Therapeutics, Inc.285 enrolled64 locationsNCT07148414
Recruiting
Phase 3
A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout
Uncontrolled Gout
Amgen270 enrolled37 locationsNCT07388498
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
Rheumatoid Arthritis
Hoffmann-La Roche160 enrolled46 locationsNCT07137598
Recruiting
Phase 2
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
Rheumatoid Arthritis
AstraZeneca320 enrolled144 locationsNCT07276581
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
UCB Biopharma SRL450 enrolled225 locationsNCT06617325
Recruiting
Phase 3
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
AstraZeneca245 enrolled73 locationsNCT07430306
Recruiting
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb223 enrolled54 locationsNCT07175285
Recruiting
Phase 3
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
Primary Sjogren's Disease
Vor Biopharma250 enrolled18 locationsNCT07404865
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Polymyositis, Dermatomyositis
AstraZeneca240 enrolled234 locationsNCT06455449
Recruiting
Phase 2
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
Radiographic Axial Spondyloarthritis
Merck Sharp & Dohme LLC315 enrolled95 locationsNCT07133633
Recruiting
Phase 2
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
AbbVie180 enrolled70 locationsNCT06972446
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
Arthritis, Psoriatic
Janssen Research & Development, LLC240 enrolled40 locationsNCT07321873
Recruiting
Phase 3
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
Primary Sjogrens Disease
argenx580 enrolled304 locationsNCT06684847
Recruiting
Phase 3
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Systemic Lupus Erythematosus
Novartis Pharmaceuticals550 enrolled127 locationsNCT06133972
Recruiting
Phase 3
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
AbbVie1,000 enrolled369 locationsNCT05843643
Recruiting
Phase 4
Secukinumab Open Label Roll-over Extension Protocol
Autoimmunity, Inflammation
Novartis Pharmaceuticals1,000 enrolled167 locationsNCT04638647
Recruiting
Phase 4
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
Psoriatic ArthritisOverweight or Obesity
Eli Lilly and Company200 enrolled55 locationsNCT06864026
Recruiting
Phase 2
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
SclerodermaRheumatoid Arthritis (RA)Sjogren Syndrome+6 more
Artiva Biotherapeutics, Inc.90 enrolled26 locationsNCT06991114
Recruiting
Phase 2
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
Psoriatic Arthritis
AbbVie120 enrolled37 locationsNCT06865105